Short answer
Nutex Health Inc. (NUTX) filed its Q1 2026 10-Q quarterly report on Apr 30, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $216M (up 2.2% year over year) with net income of $47M.
Q1 2026 key financials · XBRL
- Revenue
- $216M
- +2.2% YoY
- Net income
- $47M
- +219.9% YoY
- Operating margin
- 37.5%
- Gross margin
- 42.4%
- EPS (diluted)
- $6.52
- +154.7% YoY
Source: XBRL data from the Nutex Health Inc. (NUTX) Q1 2026 10-Q on SEC EDGAR. USD.
Nutex Health Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Arbitration cost $46.1M vs $26.3M YoY, highest disclosed cost item
- Federal IDR disputes 5,729,954 cumulatively, with 17% found ineligible
- Outlook: evolving arbitration rules, potential insurer penalties, adverse court or regulatory changes risks to collections
Risk Factors
- New dilution risk: earn-out obligations for under-construction hospitals, triggered by 24-month operational periods expiring for eight hospitals by March 31, 2026
- Shareholder dilution: 1,374,614 earn-out shares represent approximately 19.8% of outstanding shares as of March 31, 2026
- Additional dilution: approximately 47,100 shares estimated for two hospitals with periods expiring by December 31, 2026
- Share issuance formula: hospital EBITDA multiplied by 10, less capital contributions and pro rata debt, divided by the greater of stock price or $420.00
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nutex Health Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.